--Cidofovir

The US Army Medical Research Acquisition Activity proposes to award to Gilead Sciences Incorporated , 333 Lakeside Drive, Foster City, CA 94404-1147 for the purchase of FDA Approved Cidofovir for the treatment of Smallpox. Cidofovir is the only dr ug currently available to treat US troops. Competing this requirement will cause delays in the treatment of troop and would also increase the overall cost to the government. This procurement shall be under other than full and open competition procedures in accordance with FAR 6.302. This notice of intent is not a request for competitive quote. Any response to this notice must be submitted in writing to the government and show clear and convincing evidence that another system is capable of meeting the G overnments requirements and that competition of the requirement would be advantageous to the government. If no written responses are received at least fifteen (15) days after the publication of this response, the purchase will be awarded without further notice. The Point of Contact (POC) for this action is [email protected].